Jafron Biomedical Co

Jafron Biomedical Co Cash Conversion

The Cash Conversion Rate (OCF/Net Income) of Jafron Biomedical Co (300529.SZ) as of Nov 13, 2026 is 135.36 %. In the previous year, Cash Conversion Rate (OCF/Net Income) was 128.14 % — a change of 5.63% (higher).

Cash Conversion

135.36 %

YoY

5.63%

Last updated:

Cash Conversion Rate (OCF/Net Income) of Jafron Biomedical Co is 2025 135.36 % . Cash Conversion Rate (OCF/Net Income) of Jafron Biomedical Co was 2024 128.14 % . It decreases by 5.63% higher compared to the previous year.

The Jafron Biomedical Co Cash Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Conversion
Date
Cash Conversion
Jan 1, 2018
95.55 CNY
Jan 1, 2019
102.22 CNY
Jan 1, 2020
109.40 CNY
Jan 1, 2021
104.40 CNY
Jan 1, 2022
99.35 CNY
Jan 1, 2023
210.03 CNY
Jan 1, 2024
128.14 CNY
Jan 1, 2025
135.36 CNY
The Jafron Biomedical Co Cash Conversion history
YEARCash ConversionYoY
135.36 %+5.63%
128.14 %-38.99%
210.03 %+111.40%
99.35 %-4.83%
104.40 %-4.57%
109.40 %+7.02%
102.22 %+6.98%
95.55 %-10.64%
106.92 %+20.98%
88.38 %-13.66%
102.36 %+19.28%
85.82 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Jafron Biomedical Co Stock analysis

What does Jafron Biomedical Co do? Jafron Biomedical Co., Ltd. generates revenue through the research, development, production, and sale of hemoperfusion products and medical equipment. The company offers a range of items including disposable hemoperfusion devices, hemoperfusion machines, disposable bilirubin adsorbers, the DX-10 blood purification machine, suture needles, and resins bandage. These products are utilized for treating conditions such as uremia, poisoning, severe liver diseases, autoimmune diseases, and multisystem organ failure. The primary customers for these medical solutions are hospitals across China, where the company’s products are applied in more than 3000 hospitals within 31 provinces. As a China-based company, Jafron Biomedical Co., Ltd. focuses on the design, manufacture, and distribution of biological materials and medical equipment to support healthcare providers in these regions. The company operates from its headquarters in Zhuhai, Guangdong, and supports its operations with a workforce of 3,003 full-time employees. By engaging in the full lifecycle of its products from research to sale, the firm serves the medical sector with specialized equipment for blood purification and related therapeutic needs. Jafron Biomedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Jafron Biomedical Co stock

Cash Conversion Rate (OCF/Net Income) of Jafron Biomedical Co is 135.36 % in 2025.

Cash Conversion Rate (OCF/Net Income) of Jafron Biomedical Co changed from 128.14 % to 135.36 %, representing a 5.63% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Cash Conversion Rate (OCF/Net Income) Jafron Biomedical Co since 2006 – with annual values, charts, and detailed analysis.

Cash conversion measures how effectively net income converts to operating cash flow. Ratios above 100% indicate high-quality, cash-backed earnings.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Cash Conversion Rate (OCF/Net Income)'s Jafron Biomedical Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Cash Conversion Rate (OCF/Net Income)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Cash Conversion Rate (OCF/Net Income).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Jafron Biomedical Co

All Key Metrics — Jafron Biomedical Co